Beximco Pharmaceuticals PLC. (DSE:BXPHARMA)
Bangladesh · Delayed Price · Currency is BDT 113.30
+0.60 (0.53%)
At close: Jan 22, 2026
DSE:BXPHARMA Revenue
Beximco Pharmaceuticals PLC. had revenue of 12.30B BDT in the quarter ending December 31, 2024, with 12.80% growth. This brings the company's revenue in the last twelve months to 46.34B, up 11.26% year-over-year. In the fiscal year ending June 30, 2024, Beximco Pharmaceuticals PLC. had annual revenue of 44.39B with 13.05% growth.
Revenue (ttm)
46.34B
Revenue Growth
+11.26%
P/S Ratio
1.09
Revenue / Employee
41.30M
Employees
1,122
Market Cap
50.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 44.39B | 5.12B | 13.05% |
| Jun 30, 2023 | 39.27B | 4.60B | 13.26% |
| Jun 30, 2022 | 34.67B | 5.18B | 17.55% |
| Jun 30, 2021 | 29.49B | 3.88B | 15.16% |
| Jun 30, 2020 | 25.61B | 2.80B | 12.25% |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Square Pharmaceuticals PLC. | 80.13B |
| Renata | 44.03B |
| The ACME Laboratories | 37.48B |
| The IBN SINA Pharmaceutical Industry | 12.84B |
| Beacon Pharmaceuticals | 11.58B |
| Navana Pharmaceuticals | 9.52B |
| Unilever Consumer Care | 3.63B |
| Techno Drugs | 3.23B |
Beximco Pharmaceuticals PLC. News
- 1 year ago - Small Cap Stocks: Indus Gas, VAST Resources, Beximco - The Armchair Trader